Alendronate Tablet
Product Images NDC 10135-719

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Alendronate (NDC 10135-719). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Alendronate-35mg-3x4 (Alendronalte 35mg 3x4)

Alendronate-35mg-3x4 (Alendronalte 35mg 3x4)
Packaging label for Alendronate Sodium Tablets USP 35 mg by Marlex Pharmaceuticals, Inc. The label indicates a 12-count (3x4) unit dose oral tablet. Directions specify once-weekly use with detailed dosing instructions. The label includes the product name, strength, route, labeler, barcode, and distribution information.*
FDA Label Image

Alendronate-35mg-4 (Alendronate 35mg 4)

Alendronate-35mg-4 (Alendronate 35mg 4)
Alendronate Sodium Tablets, USP 35 mg oral tablets by Marlex Pharmaceuticals, Inc. The carton contains 4 tablets, labeled for once weekly dosing with directions to dispense as an exact monthly dose. The package includes barcode and NDC 10135-718-44, with warnings and handling instructions on the side and back panels.*
FDA Label Image

Alendronate-70mg-2x10 (Alendronate 70mg 2x10)

Alendronate-70mg-2x10 (Alendronate 70mg 2x10)
Alendronate Sodium Tablets USP 70 mg unit dose carton by Marlex Pharmaceuticals, Inc. The package contains 20 tablets in 2 blister packs of 10 each. The label includes dosage strength, usage instructions, and storage information. It is designed for oral administration and prescription use once weekly.*
FDA Label Image

Alendronate-70mg-3x4 (Alendronate 70mg 3x4)

Alendronate-70mg-3x4 (Alendronate 70mg 3x4)
Alendronate Sodium Tablets, USP 70 mg in tablet form by Marlex Pharmaceuticals, Inc. The packaging is labeled for once weekly oral dosage, containing 12 unit dose tablets (3x4). It includes dosage instructions, storage details, and a barcode. The label highlights the proprietary name Alendronate and the 70 mg strength.*
FDA Label Image

Alendronate-70mg-4 (Alendronate 70mg 4)

Alendronate-70mg-4 (Alendronate 70mg 4)
Packaging label for Alendronate Sodium Tablets, USP 70 mg oral tablets by Marlex Pharmaceuticals, Inc. The carton indicates a 4-tablet package for once-weekly use. It includes dosage instructions, a barcode, and distributor information listing Marlex Pharmaceuticals in New Castle, DE. The label emphasizes prescription use and dosage guidance with warnings for proper administration.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A bar chart comparing the mean percentage increase in bone mineral density (BMD) relative to placebo plus standard error (SE) for the lumbar spine, femoral neck, and trochanter sites. Data is shown separately for USA and multinational groups, with the USA generally showing higher BMD increases across all sites.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph showing cumulative incidence (%) over time (months) comparing Alendronate Sodium and Placebo groups. The graph displays a lower cumulative incidence for Alendronate Sodium than Placebo throughout the 36-month period.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
The image contains two line graphs comparing bone mineral density (BMD) percentage change from baseline over 36 months. The left graph is labeled 'US Study,' and the right 'Multinational Study.' Both show results for Alendronate Sodium 10 mg and placebo, illustrating higher BMD increases with Alendronate compared to placebo over time.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
Two bar graphs titled 'Osteoporosis Prevention Studies in Postmenopausal Women' showing the change in bone mineral density (BMD) from baseline over 2 years and 3 years. Both graphs compare Alendronate Sodium 5mg/day versus placebo, depicting BMD percentage changes at lumbar spine, femoral neck, trochanter, and total body sites.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A bar chart titled 'Studies in Glucocorticoid-Treated Patients Increase in BMD Alendronate 5 mg/day at One Year' showing mean percent increase in bone mineral density (BMD) relative to placebo with standard error for three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter. Data compares results from U.S. and Multinational studies, with higher BMD increases observed for Multinational groups at all three sites.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A line graph depicting the effect on serum alkaline phosphatase levels in Paget's Disease of Bone over 6 months. It compares the mean percentage change from baseline for alendronate 40 mg/day, etidronate 400 mg/day, and placebo groups across two studies, showing data points at baseline, 3 months, and 6 months with error bars indicating variability and sample sizes noted for each group.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of alendronate sodium showing the molecular arrangement including amino and phosphonate groups with associated water molecules (3H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.